Clinical Endoscopy

  • 제55권3호
  • /
  • Pages.372-380
  • /
  • 2022
  • /
  • 2234-2400(pISSN)
  • /
  • 2234-2443(eISSN)
대한소화기내시경학회 (The Korean Society of Gastrointestinal Endoscopy)
권호 표지
DOI QR코드

DOI QR Code

Epidemiology of early esophageal adenocarcinoma

  • Thuy-Van P. Hang (Department of Medicine, Division of Digestive Diseases, Emory University) ;
  • Zachary Spiritos (Department of Medicine, Division of Gastroenterology, Duke University) ;
  • Anthony M. Gamboa (Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University) ;
  • Zhengjia Chen (Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University) ;
  • Seth Force (Department of Surgery, Division of Cardiothoracic Surgery, Emory University) ;
  • Vaishali Patel (Department of Medicine, Division of Digestive Diseases, Emory University) ;
  • Saurabh Chawla (Department of Medicine, Division of Digestive Diseases, Emory University) ;
  • Steven Keilin (Department of Medicine, Division of Digestive Diseases, Emory University) ;
  • Nabil F. Saba (Emory Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University) ;
  • Bassel El-Rayes (Emory Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University) ;
  • Qiang Cai (Department of Medicine, Division of Digestive Diseases, Emory University) ;
  • Field F. Willingham (Department of Medicine, Division of Digestive Diseases, Emory University)
  • 투고 : 2021.05.07
  • 심사 : 2021.10.11
  • 발행 : 2022.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Endoscopic resection has become the preferred treatment approach for select early esophageal adenocarcinoma (EAC); however, the epidemiology of early stage disease has not been well defined. Methods: Surveillance Epidemiology and End Results (SEER) data were analyzed to determine age-adjusted incidence rates among major epithelial carcinomas, including EAC, from 1973 to 2017. The percent change in incidence over time was compared according to tumor subtype. Early T-stage, node-negative EAC without metastasis was examined from 2004 to 2017 when precise T-stage data were available. Results: The percent change in annual incidence from 1973 to 2017 was 767% for EAC. Joinpoint analysis showed that the average annual percent change in EAC from 1973 to 2017 was 5.11% (95% confidence interval, 4.66%-5.56%). The annual percent change appeared to plateau between 2004 and 2017; however, early EAC decreased from 2010 to 2017, with an annual percent change of -5.78%. Conclusions: There has been a 7-fold increase in the incidence of EAC, which was significantly greater than that of the other major epithelial malignancies examined. More recently, the incidence of early EAC has been decreasing. Approximately one in five patients has node negative, potentially resectable early stage disease.

키워드

과제정보

The authors wish to acknowledge Sarah Cristofaro and Dr. Ambreen Merchant for their invaluable assistance in study coordination.

참고문헌

  1. American Cancer Society. Key statistics for esophageal cancer [Internet]. Kennesaw (GA): American Cancer Society; 2021 [cited 2021 Dec 7]. Available from: https://www.cancer.org/cancer/esophagus-cancer/about/key-statistics.html.
  2. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 2013;63:232-248. https://doi.org/10.3322/caac.21185
  3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146.
  4. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119:1149-1158. https://doi.org/10.1002/cncr.27834
  5. Dubecz A, Gall I, Solymosi N, et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol 2012;7:443-447. https://doi.org/10.1097/JTO.0b013e3182397751
  6. Barnes JA, Willingham FF. Endoscopic management of early esophageal cancer. J Clin Gastroenterol 2015;49:638-646. https://doi.org/10.1097/MCG.0000000000000353
  7. National Institutes of Health. SEER*Stat software (version 8.3.9.2) [Internet]. Bethesda (MD): National Institutes of Health; 2021 [cited 2021 Dec 7]. Available from: https://seer.cancer.gov/seerstat/index.html.
  8. Greene FL, Balch CM, Fleming ID, et al. AJCC cancer staging handbook: TNM classification of malignant tumors. 6th ed. New York (NY): Springer; 2002.
  9. Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging handbook: from the AJCC cancer staging manual. 7th ed. New York (NY): Springer; 2010.
  10. National Institutes of Health. Joinpoint regression program [Internet]. Bethesda (MD): National Institutes of Health [cited 2021 Dec 7]. Available from: https://surveillance.cancer.gov/joinpoint/.
  11. Murphy CC, Sandler RS, Sanoff HK, et al. Decrease in incidence of colorectal cancer among individuals 50 years or older after recommendations for population-based screening. Clin Gastroenterol Hepatol 2017;15:903-909.e6. https://doi.org/10.1016/j.cgh.2016.08.037
  12. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. https://doi.org/10.1200/JCO.2005.04.4859
  13. Banks E, Canfell K. Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. Breast Cancer Res 2010;12:103.
  14. He H, Chen N, Hou Y, et al. Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis. Thorac Cancer 2020;11:1121-1128. https://doi.org/10.1111/1759-7714.13311
  15. Haiyu Z, Xiaofeng P, Xiangqiong M, et al. Incidence and survival changes in patients with esophageal adenocarcinoma during 1984-2013. Biomed Res Int 2019;2019:7431850.
  16. Then EO, Lopez M, Saleem S, et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol 2020;11:55-64. https://doi.org/10.14740/wjon1254
  17. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200-1206. https://doi.org/10.1136/gut.2007.142539
  18. Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005;61:506-514. https://doi.org/10.1016/S0016-5107(05)00063-5
  19. Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007;39:1086-1091. https://doi.org/10.1055/s-2007-966788
  20. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007;65:3-10. https://doi.org/10.1016/j.gie.2006.04.033
  21. May A, Gossner L, Pech O, et al. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy 2002;34:604-610. https://doi.org/10.1055/s-2002-33236
  22. Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003;57:854-859. https://doi.org/10.1016/S0016-5107(03)70020-0
  23. Manner H, Pech O, Heldmann Y, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 2013;11:630-635. https://doi.org/10.1016/j.cgh.2012.12.040
  24. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014;146:652-660.e1. https://doi.org/10.1053/j.gastro.2013.11.006
  25. Gamboa AM, Kim S, Force SD, et al. Treatment allocation in patients with early-stage esophageal adenocarcinoma: prevalence and predictors of lymph node involvement. Cancer 2016;122:2150-2157. https://doi.org/10.1002/cncr.30040
  26. Ajani JA, D'Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 2015;13:194-227. https://doi.org/10.6004/jnccn.2015.0028
  27. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. https://doi.org/10.3322/caac.21590
  28. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013;2013:291546.
  29. Nieman KM, Romero IL, Van Houten B, et al. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013;1831:1533-1541. https://doi.org/10.1016/j.bbalip.2013.02.010
  30. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am 2014;43:161-173. https://doi.org/10.1016/j.gtc.2013.11.009
  31. Ness-Jensen E, Hveem K, El-Serag H, et al. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2016;14:175-182.e1-e3. https://doi.org/10.1016/j.cgh.2015.04.176
  32. Schlottmann F, Dreifuss NH, Patti MG. Obesity and esophageal cancer: GERD, Barrett's esophagus, and molecular carcinogenic pathways. Expert Rev Gastroenterol Hepatol 2020;14:425-433. https://doi.org/10.1080/17474124.2020.1764348